Business
Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
Raanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an accepted and standard comparator used in nasal barrier products. The study,
About this update from Polyrizon Ltd.
[{"type":"text","content":"Raanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an accepted and standard comparator used in nasal barrier products.","length":490,"tagName":"p"},{"type":"text","content":"The study, conducted using a validated in-vitro Transwell permeability system designed to mimic allergen transfer into the nasal mucosa, assessed PL-14’s ability to inhibit transfer of Der p 1, a major clinically relevant house dust mite allergen commonly associated with allergic rhinitis and asthma.","length":301,"tagName":"p"},{"type":"text","content":"Key findings demonstrated that PL-14 significantly reduced allergen transfer at all time points compared with HPMC, including early time points that are considered critical for preventing allergen-triggered immune activation. Statistical analysis showed that PL-14 significantly reduced Der p 1 transfer compared with HPMC at every tested time point (1, 2, 4, 6, and 24 hours), with p-values ≤ 0.0042.","length":401,"tagName":"p"},{"type":"text","content":"Highlights from the Study","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"PL-14 showed markedly lower allergen transfer versus HPMC throughout the experiment, supporting a consistent barrier effect. ","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"At 1 hour, PL-14 demonstrated very low allergen penetration, with measured mean concentrations of ~20.6 ng compared with ~1354.4 ng for HPMC. ","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"HPMC exhibited substantial and time-dependent allergen permeation, rising to mean concentrations of ~5201.2 ng at 24 hours, consistent with limited barrier function. ","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"PL-14 maintained low mean allergen levels across all time points, reaching a maximum mean value of ~141.2 ng at 4 hours, supporting a sustained protective effect.","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":592,"olType":false},{"type":"...